Lonza Group (OTCMKTS:LZAGY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company’s Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. “
Shares of OTCMKTS:LZAGY opened at $23.63 on Thursday. Lonza Group has a 1 year low of $18.80 and a 1 year high of $29.56.
ILLEGAL ACTIVITY WARNING: “Lonza Group (LZAGY) Upgraded to Hold at Zacks Investment Research” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/lonza-group-lzagy-upgraded-to-hold-at-zacks-investment-research.html.
About Lonza Group
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients for life-saving medicines; manufactures commercial bulk drug substance of monoclonal antibodies and recombinant proteins from mammalian cell cultures; and chemical contract manufacturing services, such as microbials, peptides, and small molecules.
Get a free copy of the Zacks research report on Lonza Group (LZAGY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.